Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Progenitor Cell Mobilization

Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma

Bone Marrow Transplantation volume 33, pages 703–707 (2004)Cite this article

Summary:

We mobilized peripheral blood stem cells (PBSC) following CHOP plus rituximab (CHOP-R) therapy, and compared with the findings following CHOP therapy without rituximab. All patients were given G-CSF starting from day 11 after CHOP therapy. Patients in the CHOP-R group (n=8) were given rituximab on day 12. Target CD34+ cells number was collected in a single leukapheresis on day 14, from all the eight patients in the CHOP-R group. PBSC mobilization kinetics, CD34+ cells yield and colony-forming ability in the graft collection, toxicity during mobilization, and engraftment after transplantation of CHOP-R group were not significantly different from those in the CHOP group (n=8). In all patients given CHOP-R therapy, CD20+ cells and immunoglobulin heavy chain (IgH) rearrangement in the graft collection were undetectable by flow-cytometric analysis and Southern blot analysis, respectively, but with PCR analysis two of eight grafts were positive for IgH rearrangement. While further studies are needed to evaluate the efficacy of purging and the outcome of patients undergoing autologous transplantation, CHOP-R therapy can be safely and effectively used in the mobilization phase of PBSC collection, without excess clinical toxicity or deleterious effect on PBSC mobilization kinetics or engraftment time.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Shipp MA, Abeloff MD, Antman KH et al. International consensus on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin’s lymphomas: report of the jury. J Clin Oncol 1999; 17: 423–429.

    Article  CAS  Google Scholar 

  2. Horning SJ . High-dose therapy and transplantation for low-grade lymphoma. Hematol Oncol Clin North Am 1997; 11: 919–935.

    Article  CAS  Google Scholar 

  3. Gribben JG, Neuberg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449–3457.

    CAS  Google Scholar 

  4. Freedman AS, Gribben JG, Neuberg D et al. High dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780–2786.

    CAS  Google Scholar 

  5. Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525–1533.

    Article  CAS  Google Scholar 

  6. McQuaker IG, Haynes AP, Anderson S et al. Engraftment and molecular monitoring of CD34+ peripheral-blood stem-cell transplants for follicular lymphoma: a pilot study. J Clin Oncol 1997; 15: 2288–2295.

    Article  CAS  Google Scholar 

  7. Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al. IDEC-C2B8: results of phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol 1997; 15: 3266–3274.

    Article  CAS  Google Scholar 

  8. Lazzarino M, Arcaini L, Bernasconi P et al. A sequence of immuno-chemotherapy with rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 2002; 116: 229–235.

    Article  CAS  Google Scholar 

  9. Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864–869.

    CAS  Google Scholar 

  10. Voso MT, Pantel G, Weis M et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin’s lymphoma. Br J Haematol 2000; 109: 729–735.

    Article  CAS  Google Scholar 

  11. Flohr T, Hess G, Kolbe K et al. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant 2002; 29: 769–775.

    Article  CAS  Google Scholar 

  12. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993; 328: 1002–1006.

    Article  CAS  Google Scholar 

  13. Coiffier B, Gisselbrecht C, Vose JM et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol 1991; 9: 211–219.

    Article  CAS  Google Scholar 

  14. Sawada K, Sato N, Kohno M et al. Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin’s lymphoma: a pilot study for a leukocyte count oriented regimen. Leuk Lymphoma 1995; 20: 103–109.

    Article  CAS  Google Scholar 

  15. Takano H, Sawada K, Sato N et al. Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin’s lymphoma. Leuk Lymphoma 1996; 21: 473–478.

    Article  CAS  Google Scholar 

  16. Sato N, Sawada K, Koizumi K et al. In vitro expansion of human peripheral blood CD34+ cells. Blood 1993; 82: 3600–3609.

    CAS  Google Scholar 

  17. Clarke BJ, Housman D . Characterization of an erythroid precursor cell of high proliferative capacity in normal human peripheral blood. Proc Natl Acad Sci USA 1977; 74: 1105–1109.

    Article  CAS  Google Scholar 

  18. Tarumi T, Sawada K, Koizumi K et al. A pilot study of a response oriented chemotherapeutic regimen combined with autologous peripheral blood progenitor cell transplantation in aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 1999; 34: 361–371.

    Article  CAS  Google Scholar 

  19. Buckstein R, Imrie K, Spaner D et al. Stem cell function and engraftment is not affected by ‘in vivo purging’ with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin’s lymphoma. Semin Oncol 1999; 26: 115–122.

    CAS  Google Scholar 

  20. Friedman J, Lazarus HM, Koc ON . Autologous CD34+ enriched peripheral blood progenitor cell (PBPC) transplantation is associated with higher morbidity in patients with lymphoma when compared to unmanipulated PBPC transplantation. Bone Marrow Transplant 2000; 26: 831–836.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank I Sato for technical assistance.

Author information

Authors and Affiliations

  1. Department of Internal Medicine II, Hokkaido University School of Medicine, Sapporo, Japan

    T Endo, K Koizumi, M Nishio, K Fujimoto, T Sakai, K Kumano, M Obara & T Koike

  2. Blood Transfusion Service, Hokkaido University Medical Hospital, Sapporo, Japan

    N Sato

  3. Hokkaido Red Cross Blood Center, Sapporo, Japan

    Y Mogi & H Ikeda

Authors
  1. T Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Mogi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Koizumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Nishio
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Fujimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Kumano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Obara
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. T Koike
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Endo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Endo, T., Sato, N., Mogi, Y. et al. Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 33, 703–707 (2004). https://doi.org/10.1038/sj.bmt.1704413

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704413

Keywords

This article is cited by

Search

Advanced search

Quick links